Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZOPT vs ACETAZOLAMIDE SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.
Open-angle glaucoma,Ocular hypertension
Treatment of open-angle glaucoma and secondary glaucoma,Preoperative and perioperative reduction of intraocular pressure in acute angle-closure glaucoma,Treatment of edema due to congestive heart failure when other diuretics are ineffective,Adjunctive treatment of epilepsy (centrencephalic epilepsies, absence seizures),Prophylaxis and treatment of acute mountain sickness
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 m L/min).
10-15 hours (prolonged in renal impairment; cirrhosis increases t1/2 to 20-30 h).
Not significantly metabolized; primarily excreted unchanged in urine via renal tubular secretion.
Acetazolamide is minimally metabolized in the liver, with the majority of the drug excreted unchanged in the urine. The primary metabolic pathway involves oxidation of the thiadiazole ring, but this is a minor route. The drug is not extensively biotransformed; hepatic metabolism accounts for less than 10% of elimination.
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Primarily renal (90% unchanged via tubular secretion). <2% biliary/fecal.
Approximately 33% bound to plasma proteins (mainly albumin).
70-90% (mainly carbonic anhydrase in RBCs; low affinity for albumin).
Volume of distribution is approximately 0.35 L/kg, indicating distribution primarily into extracellular fluid.
Approximately 0.2-0.3 L/kg; mainly confined to extracellular fluid and highly perfused tissues.
Ocular bioavailability is not quantified due to local administration; systemic bioavailability after topical ocular dosing is approximately 70% via nasolacrimal absorption.
Oral: ~90-100% (rapidly absorbed; food may delay). Intramuscular: not recommended (acidic p H).
No dosage adjustment required for systemic absorption is minimal. However, use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential metabolite accumulation.
GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: avoid or use with extreme caution.
No dosage adjustment required for systemic absorption is minimal. Use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or extend interval to 24-48 hours. Child-Pugh C: avoid use.
Approved for children ≥2 years: one drop in the affected eye(s) twice daily. For children <2 years: safety and efficacy not established.
For edema: 5 mg/kg IV or IM once daily. For glaucoma: 10-15 mg/kg/day IV or IM in divided doses every 6-8 hours.
No specific dose adjustment required. Monitor for ocular irritation and systemic effects, as elderly patients may be more sensitive to adverse reactions such as hypotension or fatigue.
Initiate at lowest adult dose; monitor renal function and electrolytes; adjust based on creatinine clearance.
None
None
Sulfonamide allergy (cross-reactivity possible),Corneal endothelial damage (risk increased with low endothelial cell count),Bacterial keratitis (with concomitant use of topical corticosteroids or ocular trauma),Contaminated dropper tip may cause ocular infections
Use with caution in patients with hepatic cirrhosis, as acetazolamide can precipitate hepatic encephalopathy due to increased ammonia levels,May cause metabolic acidosis, which can be severe with prolonged use; monitor serum electrolytes and bicarbonate levels,Can precipitate renal calculi due to decreased urinary citrate excretion; ensure adequate hydration,May cause drowsiness, confusion, or ataxia; caution when operating machinery or driving,Use with caution in patients with respiratory acidosis or chronic obstructive pulmonary disease, as metabolic acidosis may worsen respiratory function,Monitor for signs of hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis,May cause hematologic reactions such as agranulocytosis, aplastic anemia, and thrombocytopenia; monitor blood counts
Hypersensitivity to brinzolamide or any sulfonamides,Severe renal impairment (Cr Cl <30 m L/min) or hyperchloremic acidosis
Known hypersensitivity to acetazolamide or any sulfonamide-derivative (although cross-reactivity may not occur, caution is advised),Severe hepatic insufficiency or cirrhosis with risk of hepatic encephalopathy,Severe renal impairment (e.g., anuria, glomerular filtration rate <10 m L/min),Metabolic acidosis,Hyponatremia or hypokalemia,Concurrent use with high-dose aspirin (risk of metabolic acidosis and increased salicylate toxicity)
No significant food interactions known. However, avoid excessive salt intake if using systemic carbonic anhydrase inhibitors; for AZOPT, ocular use minimizes systemic effects, but caution in patients with electrolyte imbalances.
No specific food interactions reported. However, high-sodium foods may counteract the diuretic effect. Maintain adequate fluid intake to prevent kidney stones. Avoid large amounts of caffeine as it may increase diuresis and electrolyte loss.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in rabbits and 20 mg/kg/day in rats. However, due to potential for fetal harm (systemic carbonic anhydrase inhibition causing acidosis), use only if clearly needed. First trimester: avoid if possible; second/third trimesters: monitor for maternal acidosis.
Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human data limited but suggests potential teratogenicity. Second and third trimesters: may cause fetal metabolic acidosis, electrolyte disturbances, and growth restriction due to carbonic anhydrase inhibition.
It is not known if brinzolamide is excreted in human milk. In animal studies, brinzolamide was detected in milk of lactating rats. Caution is advised; consider risk vs benefit. M/P ratio: unknown.
Acetazolamide is excreted into breast milk in low amounts. M/P ratio is approximately 0.25. Infant exposure is minimal but may cause metabolic acidosis or diuresis. Caution is advised; monitor infant for signs of acidosis or dehydration.
No specific dose adjustments recommended; however, due to potential for increased systemic absorption during pregnancy (increased blood volume and ocular changes), monitor intraocular pressure closely. Use the lowest effective dose. Pharmacokinetic changes: unknown; adjust based on clinical response.
Dose adjustments may be necessary due to increased renal clearance and volume of distribution in pregnancy. Monitor therapeutic effect and adverse reactions; consider starting at lower doses and titrating based on response. No standardized guidelines exist; individualize therapy.
AZOPT (brinzolamide ophthalmic suspension) is a carbonic anhydrase inhibitor used for lowering intraocular pressure in ocular hypertension or open-angle glaucoma. Shake well before use; may cause transient blurred vision. Use with caution in sulfonamide allergy patients. Monitor for corneal edema and electrolyte disturbances in prolonged use.
Acetazolamide is a carbonic anhydrase inhibitor used for altitude sickness prophylaxis, glaucoma, and as a diuretic. Monitor for metabolic acidosis, especially in elderly or renal impairment. Can cause hypokalemia; check serum potassium. Contraindicated in hepatic cirrhosis due to risk of hepatic encephalopathy. May cause paresthesias, especially in hands and feet, which are harmless but can be distressing.
Shake the bottle vigorously before each use.,Remove contact lenses before instilling and wait at least 15 minutes before reinserting.,Apply pressure to the tear duct (punctal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not touch the dropper tip to any surface to avoid contamination.,May cause temporary blurred vision; avoid driving or operating machinery until vision clears.,Report any eye pain, redness, or vision changes to your healthcare provider.
Take with food to reduce gastrointestinal upset.,May cause tingling in fingers, toes, or face; this is usually temporary and not harmful.,Drink plenty of fluids unless otherwise instructed to prevent kidney stones.,Avoid alcohol as it may increase side effects like dizziness.,Do not drive or operate machinery until you know how this medication affects you, as it may cause drowsiness or blurred vision.,Report any signs of unusual bleeding, bruising, or signs of infection to your healthcare provider.,Take exactly as prescribed; do not stop suddenly without consulting your doctor.,If used for altitude sickness, start 24-48 hours before ascent and continue for 48 hours at high altitude.
No interactions on record
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZOPT vs ACETAZOLAMIDE SODIUM, answered by our medical review team.
AZOPT is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.. ACETAZOLAMIDE SODIUM is a Carbonic Anhydrase Inhibitor that works by Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZOPT and ACETAZOLAMIDE SODIUM depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZOPT is: One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.. The standard adult dose of ACETAZOLAMIDE SODIUM is: Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZOPT and ACETAZOLAMIDE SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZOPT is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in ra. ACETAZOLAMIDE SODIUM is classified as Category C. Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.